CYPH underwent a complete business transformation, changing from Leap Therapeutics to Cypherpunk Holdings with a name change in November 2025, while dramatically improving financial performance with a swing from -$67.6M to +$4.8M net income.
This represents a fundamental pivot away from biotechnology operations (evidenced by the 55% reduction in R&D expenses) toward what appears to be cryptocurrency-related business based on the new "Cypherpunk" name and risk factor mentions of cryptocurrency markets. The massive 338% increase in stockholders' equity combined with profitability suggests either a major capital raise, asset acquisition, or successful business model transition that investors need to evaluate carefully.
The company achieved a remarkable financial turnaround, swinging from a $67.6M net loss to $4.8M profit while dramatically strengthening its balance sheet with stockholders' equity surging 338% to $153.5M and total assets growing 232% to $163.2M. However, cash declined significantly by 70% to $14.0M, suggesting major capital deployment or business investments, while the 55% reduction in R&D expenses confirms the strategic shift away from biotechnology operations. The overall picture shows a company that has successfully executed a major business transformation with substantially improved financial health, though the cash burn and business model change require careful monitoring.
Equity base grew 338% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Current assets grew 237.4% — improving short-term liquidity or inventory/receivables build.
Asset base grew 232.2% — expansion through organic growth, acquisitions, or capital deployment.
Net income grew 107.1% — bottom-line growth signals improving overall business health.
Cash declined 70.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current liabilities reduced — improved short-term financial position and working capital health.
Capital expenditure jumped 56.3% — major investment cycle underway; assess returns on deployment.
R&D spending cut 55.1% — could signal cost discipline or concerning reduction in innovation investment.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Interest expense surged 31.7% — significant debt increase or rising rates materially impacting earnings.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →